Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

HNNS > HNS53, HNS54 Molecular Basis Of Neurological Diseases I and II > Flashcards

HNS53, HNS54 Molecular Basis Of Neurological Diseases I and II Flashcards

1
Q

Neurological diseases

A
  1. ***Huntington’s disease
  2. Infection (HIV, meningitis, prion etc.)
  3. Injury
  4. Autoimmune (Myasthenia gravis)
  5. Inflammation (Multiple sclerosis)
  6. ***Motor neuron disorders (Parkinson’s disease)
  7. Synaptic transmission
  8. ***Neurodegenerative (Alzheimer’s disease)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Huntington’s disease

A

Autosomal dominant

  • every generation
  • both male and female affected
  • highly penetrant

Typically begin in mid-life (30-45)

NO current treatment to prevent / delay progression of HD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Clinical features of HD

A
  1. Motor
    - Chorea
    - Gait abnormalities
    - In-coordination
    - Dysarthria
    - Eye movement abnormalities
    - Rigidity / Bradykinesia / Dystonia (esp. in young onset cases)
  2. Cognitive
    - Subcortical structures
    - Frontal type problems (impaired executive functions): problem solving, planning etc.
    - Mental slowing
    - Poor attention / memory difficulties
    - Language generally well-preserved
    - ALL patients will develop global dementia with time
    - Need to check not depressed esp. they can get worse quickly
  3. Psychiatric
    - Personality change
    - Apathy, irritability, disinhibition, emotionally labile
    - Mood swings
    - Social withdrawal
    - Poor self care and alcoholism
    - Criminal record due to mental problem
  4. Other features (fits in young onset cases, sleep disturbance, weight loss)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Clinical stages of HD

A
  1. Early
    - progressive emotional, psychiatric, cognitive disturbances
  2. Later
    - motor signs
    - progressive dementia
  3. Advanced
    - unable to walk
    - poor dietary intake
    - long term institutional care
  4. Swallowing difficulties —> Aspiration pneumonia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Neuropathology of HD

A
  • Brain specific
  • ***Striatal atrophy
  • Prominent neuronal loss (Caudate nucleus + Putamen)
  • Selective for **medium spiny neurons (Special type of **GABAergic inhibitory neurons)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Etiology of HD: Mapping HD gene

A
  • Use genetic linkage
  • Abnormal gene contain multiple **CAG repeats —> multiple **glutamine (abnormal Huntington (htt) protein)
  • > 36 CAG repeats —> HD (>39 definitely pathogenic)
  • larger number of repeats —> develop symptoms at earlier age

Huntington gene:

  • > 200,000 base pairs, 67 exons
  • 348kDa protein (3144 a.a.)
  • Polyglutamine sequence (CAG repeats)
  • ***Ubiquitous expression (highest levels in CNS neurons)
  • ***Widespread subcellular localisation (clathrin-coated vesicles, endosomal compartment, microtubule)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Key cellular pathogenic mechanisms in HD

A

Multiple glutamine repeats (每一個獨立mechanism)

  1. Conformational change of protein —> unfolding / ***abnormal folding
  2. ***Accumulation in cytoplasm
  3. Impairment of calcium signaling in ER + homeostasis
  4. ***Mitochondrial dysfunction
  5. Translocate to nucleus (***impair BDNF gene transcription, form intranuclear inclusions)
  6. Alters ***vesicular transport and recycling

—> ALL eventually lead to Prominent loss of medium spiny neurons (Special type of ***GABAergic inhibitory neurons)
—> Striatal atrophy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Gene therapy of HD

A

AMT-130:

  • consist of AAV5 vector
  • carrying an **artificial micro-RNA —> tailored to **silence mutant Huntington gene
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Parkinson’s disease

A
  • 2nd most common neurodegenerative disorder
  • ***Majority sporadic, 10-20% family history
  • Monogenic rare
  • ***Male > Female
  • Autosomal Dominant / Recessive (both occur)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Clinical features of PD

A

四寶: Resting tremor, Muscle rigidity, Bradykinesia, Abnormal gait/posture

  1. Tremor-at-rest
  2. Bradykinesia, Hypokinesia, Akinesia
  3. Rigidity
  4. Flexed posture of neck, trunk, limbs
  5. Loss of postural reflexes
  6. Freezing phenomenon
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

***Pathological features

A
  1. Loss of monoamine neurons in Substantia nigra pars compacta + Locus ceruleus
    - Presence of Lewy bodies (inclusion bodies within neuron containing α-Synuclein etc.) + ↑ Glial cells
  2. Depigmentation
    - loss of ***Neuromelanin (derived from oxidised dopamine) in Substantia nigra pars compacta + Locus ceruleus

Overall:
Dopamine depletion in Substantia nigra + Nigrostriatal pathway to Caudate + Putamen
—> ↑ inhibition of Thalamus + ↓ excitatory input to Motor cortex
—> Bradykinesia and other parkinsonism signs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Lewy bodies

A
  • Intracellular eosinophilic masses made up of ***α-Synuclein and other proteins
  • ***Pathologic hallmark of PD
  • Not specific to PD, also found in other neurodegenerative diseases and normal elderly people
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

***Gene localisations identified for PD

A
  1. PARK1 gene —> Autosomal ***dominant inheritance —> α-Synuclein mutations and aggregation into Fibrillar forms —> Lewy bodies
  2. PARK2 gene —> Autosomal ***recessive inheritance —> inactivation of Ubiquitin ligase (Parkin) —> accumulation of Parkin substrates (targeted protein) in neurons —> Selective toxicity to Dopamine neurons
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Dynamic aggregation processes of α-Synuclein

A
  • α-Synuclein is unfolded in solution but form helix-like structures in association with membrane
  • normally exist in equilibrium between membrane and cytosol
  • Pathological conditions (Autosomal Dominant mutation of α-Synuclein gene):
    α-Synuclein **aggregates via small oligomeric intermediates
    —> larger **    fibrillar forms (β-sheet)
    —(+ Ubiquitin)—> ***Lewy bodies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Parkin protein

A
  • E3 Ubiquitin ligase
  • 2 domains: RING-box domain + Ubiquitin domain
  • 465 a.a.
  • Autosomal Recessive juvenile PD + Early onset Recessive PD
  1. Ubiquitin-Proteasome pathway:
    - E1 transfer Ub to E2
    —> E2-Ub attach to RING-box
    —> transfer Ub to targeted protein
    —> attachment of Polyubiquitin chains to targeted proteins (將Ubiquitin (死亡signal) attach落targeted protein度)
    —> degradation
    - ***Inactivation of E3 Ubiquitin ligase (Parkin) —> accumulation of Parkin substrates (targeted protein) in neurons —> Selective toxicity to Dopamine neurons
  2. Protective role in mitochondria
  3. Dopaminergic neurons may also be more vulnerable because of ***intrinsic exposure to oxidative stress —> protein damage and misfolding
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

PD summary

A
  • Neurodegenerative disease with movement disorder + neuropsychiatric clinical features
  • Majority sporadic, some genetic forms
  • Progressive, chronic, incurable
  • ***Pathology:
    1. Neuronal loss in Substantia nigra pars compacta + Locus coeruleus
    2. Depigmentation (loss of Neuromelanin)

Example of gene mutation:

  • **α-Synuclein accumulation —> **Lewy body
  • ***Inactivation of Parkin —> E3 Ubiquitin ligase —> Proteins targeted for degradation
17
Q

Alzheimer’s disease

A
  • ***Age-dependent neurodegenerative disorder that results in progressive loss of cognitive function
  • Memory loss, unusual behaviour, personality changes, decline in thinking abilities
  • Burden of AD: emotional, physical, financial stress on family members
  • most common cause of dementia among elderly in HK

Risk factors:

  • Age
  • Family history dementia esp. early onset
  • Down’s syndrome
  • Severe head injury
  • Genetic factors
  • Lifestyles
  • Vascular risk factors?
18
Q

Classification of AD

A
  1. By age of onset
    - Early onset: <= 65
    - Late onset: >65
  2. By family history
    - ***Sporadic case ~90%
    - Familial case ~10%
19
Q

Cognitive features of AD

A
  1. ***Memory
    - impaired anterograde episodic memory
    - delayed recall of stories
    - Word List learning
    - impaired association (visual memory and new learning)
    - working memory spared
  2. Attentional + ***Executive deficits
    - poor concentration
    - problem with complex tasks
    - selective attention
    - executive functions
    - Wisconsin Card Sorting test —> test working memory
  3. ***Language and knowledge
    - impaired semantic memory
    - category fluency
    - word definitions
    - word finding esp. proper names
    - later phonological and syntactic deficits
  4. ***Visuospatial and Perceptual inabilities
    - impaired drawing esp. 3D
    - apraxia mainly conceptual
20
Q

Neuropsychiatric features of AD

A
  1. Apathy
  2. Depression
  3. Anxiety
  4. Delusion (rare in early stage)
  5. Paranoia
  6. Phantom lodger (inability to recognize one’s own reflected image)
  7. Agitation and disruptive behaviour common later
21
Q

Diagnostic criteria of AD

A

According to NINCDS-ADRDA alzheimer’s criteria:
“Probable AD”:
1. Deficits in >=2 areas of cognition
2. MMSE score <24, plus neuropsychological test evaluation
3. Progressive worsening of cognitive function

Diagnostic methods:

  1. ***Neuropsychological
  2. Structural imaging
  3. Functional ***imaging (PET, SPECT)
  4. ***Biological markers (CSF amyloid, tau protein etc.)
22
Q

***Pathology of AD

A
  1. Shrinkage of Cortex (esp. Superior frontal association cortex)
  2. Shrinkage of Hippocampus (+ Entorhinal cortex, Inferior temporal cortex)
    —> enlarged Ventricles
23
Q

***Pathological hallmarks in AD brain

A
  1. **Amyloid plaques
    - Extracellular aggregation of **    Amyloid-β protein, other association proteins, non-nerve cells
  2. **Neurofibrillary tangles
    - Intracellular abnormal form of **    microtubule associated protein: Tau —> Hyperphosphorylated —> captured in NFT —> microtubules destabilised + dissociation —> reduced axonal transport —> AD
  3. Significant decrease in ACh transferase + Loss of cholinergic neurons
24
Q

Familial AD

A
  1. ***Autosomal dominant families in Early onset AD
  2. ***Familial aggregation in Late onset cases (also Autosomal dominant, with age-dependence but high penetrance)
  3. ***MZ twins (~40-50%) vs DZ twins (~10-20%) concordance rate
25
Q

***Genetics of Early onset AD

A

Three ***autosomal dominant genes responsible for almost ALL large early-onset AD families

  1. ***APP
  2. ***PSEN1 (most mutations and most families)
  3. ***PSEN2

Still, ~50% of early-onset AD cases remain genetically unexplained

26
Q

APP processing and Amyloid plaque

A

One domain of ***Transmembrane protein

  • β-secretase —> cleave APP to form C99 —> ***γ-secretase (encoded by PSEN1) —> Aβ40/Aβ42 (—> degraded by Neprilysin, IDE, APOE)
  • α-secretase —> cleave APP to produce C83

Mutation of APP / PSEN1:
- affect cleavage activity —> ↑ Aβ40/Aβ42 —> Amyloid-β accumulation —> Amyloid plaque

27
Q

Neurofibrillary tangles

A

Tau protein:
- structural protein in neuron
—> binds and **stabilise microtubule
—> help to **transport

Alzheimer’s disease:
- Tau protein ***hyperphosphorylated
—> Tau ***sequestered / captured in Neurofibrillary tangles
—> loss of Tau binding to microtubules
—> microtubule ***dissociation
—> reduced ***axonal transport
—> AD
28
Q

ApoE: Risk factor of AD

A

Risk factor for ***Sporadic AD

Mechanism for association with AD: likely **Aβ clearance + **neuronal repair

Apolipoprotein E
- transport plasma lipids within tissues
- ***clearance of Amyloid-β at BBB
- immune response
- synaptic maintenance
- 3 alleles:
—> ε3 (most common, normal allele)
—> ε2 (protective: ↓ frequency in AD cases but risk factor for CVD)
—> ε4 (risk allele: ↑ frequency in AD cases)
  • **ε4 allele:
  • ↑ risk of developing AD
  • ↓ age of onset of AD
29
Q

Potential treatment for AD

A

Aducanumab

  • targets aggregated forms of β-amyloid —> reducing its buildup
  • antibody given IV once a month
30
Q

Amyotrophic lateral sclerosis (ALS)

A
  • ***Sporadic ALS: 90%
  • Familial ALS: 10%
  • average age of ALS onset: 55
  • 50% patients die after 3 years
31
Q

Symptoms of ALS

A
  1. Tripping, stumbling, falling
  2. Loss of muscle control and strength in hands, arms
  3. Difficulty speaking, swallowing, breathing
  4. Chronic fatigue, muscle twitching / cramping

Caused by:

  1. Upper motor neuron damage:
    - Stiffness (spasticity)
    - Muscle twitching (fasciculations)
    - Muscle shaking (clonus)
  2. Lower motor neuron damage:
    - Muscle weakness
    - Muscle shrinking (atrophy)
32
Q

Spinal onset vs Bulbar onset of ALS

A

Spinal onset (problem begin in limbs):

  • 75%
  • 6 months of progressive weakness of hand grip
  • fasciculations of muscle in affected limb
  • cramps and spasms
  • weight loss +

Bulbar onset (problem begin with speaking / swallowing):

  • 25%
  • commoner in elderly women
  • 9 months of progressive difficulty in speaking / swallowing
  • weight loss +++
  • inappropriate laughing and crying
  • breathless when lying flat
33
Q

Diagnosis of ALS

A
  • ***NO diagnostic test
  • Mainly based on progressive pure motor syndrome
  • not explained by lesion in a single anatomical site
    —> mean delay in diagnosis: 1 year
  1. EMG: supportive paraclinical test
  2. inappropriate laughing / crying
34
Q

Pathology of ALS

A
  1. ***Brain atrophy (some areas more severe)
  2. Neuronal loss in ***Corticospinal tract
  3. Unique microscopic features
    - **Bunina bodies in motor neurons
    - **    “Skeins”, **Hyaline bodies, **Dystrophic neurites in anterior horn cells
35
Q

Genetics of ALS

A
  1. ***SOD1 gene
    - Autosomal dominant
    - typical ALS
  2. ***Dynactin gene
    - Autosomal dominant
    - adult onset, slow progressive, early vocal cord paralysis
36
Q

SOD1 mutations

A
  • 15-20% of Familial ALS (1-2% of all cases)
  • 100 mutations —> Intracellular aggregate, Protein folding / degradation failure

Normal SOD1:
- 2 dimers
- each bind to Cu + Zn ion
- function of SOD1: reduction of Cu2+ —> Cu1+
—> regulate dismutation of superoxide ion into hydrogen peroxide H2O2

SOD1 mutation in Familial ALS:

Loss of physiological function
1. ***Impaired dismutase activity

Gain of toxic function
2. ***Aberrant redox chemistry: due to changes in conformation of SOD1, that leave the channel (responsible for accepting superoxide ion) able to accept larger molecules

  1. ***Protein instability and SOD1 aggregation (characteristic of all SOD1 mutants)
    —> mitochondrial dysfunction, oxidative stress
37
Q

Dynactin gene

A

Dynactin: responsible for ***Retrograde transport in axons (Dynein/Dynactin)

Mutation in Dynactin: ***impaired Retrograde transport

Symptoms:
- adult onset, slow progressive, early vocal cord paralysis

38
Q

***Summary of HT, PD, AD, ALS

A

HD:

  • Autosomal dominant
  • Brain specific: Striatum (Caudate + Putamen)
  • Loss of Medium spiny neurons (GABAergic inhibitory neurons)
  • ***Huntington CAG repeats >36 —> Multiple glutamine repeats
  • ***Striatal atrophy
  • Mutant protein aggregation
  • Chorea + Psychiatric disturbance + Cognitive impairment

PD:

  • Autosomal dominant / recessive
  • Substantia nigra pars compacta + Locus ceruleus
  • Loss of Neuromelanin, Monoamine neurons, Monoamine —> Dopamine depletion
  • **α-Synuclein, **Parkin / E3 Ubiquitin ligase (PARK1/2)
  • ***Lewy bodies
  • Mutant protein aggregation
  • Bradykinesia, Rigidity, Resting tremor, Postural instability, Gait disturbance

AD:

  • Cerebral cortex + Subcortical regions (Hippocampus) atrophy
  • Loss of neurons and synapses
  • **APP, **Presenilin 1/2, **ApoE, **Tau
  • Neurofibrillary tangle (Hyperphosphorylated Tau): Transentorhinal region + Hippocampus
  • ***Amyloid plaque: Frontal + Posterior cingulate + Posterior association cortices
  • Mutant protein aggregation
  • Memory loss, behavioural abnormalities

ALS:

  • Autosomal dominant
  • Brain + Brainstem + Spinal cord
  • Motor neurons loss
  • **SOD1, **Dynactin gene
  • **Bunina bodies, **Hyaline bodies, ***“Skeins”
  • Mutant protein aggregation
  • Muscle weakness, muscular atrophy, spasticity, eventually paralysis

HNNS (58 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions